Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 31;14(2):20200445.
doi: 10.4022/jafib.20200445. eCollection 2021 Aug.

UBLED AF (Uninterrupted BLackpool EDoxaban vs Warfarin vs Rivaroxaban in Atrial Fibrillation/Flutter ablation) Study

Narendra Kumar  1 , Noha Elbanhawy  1 , Moinuddin Choudhury  1 , Rahul Potluri  2 , Shajil Chalil  1 , Khalid Abozguia  2
Affiliations

UBLED AF (Uninterrupted BLackpool EDoxaban vs Warfarin vs Rivaroxaban in Atrial Fibrillation/Flutter ablation) Study

Narendra Kumar et al. J Atr Fibrillation. .

Abstract

Aim: Catheter ablation in patients with atrial fibrillation (AF)/atrial flutter carries a risk of thromboembolism and major bleeding. In light of recent prospective trial data on the safety and efficacy of uninterrupted edoxaban in patients undergoing AF/flutter ablation, real-world Data was aimed for validation.

Methods: A total of 228 patients who underwent AF/atrial flutter ablation over 14 months at our centre were retrospectively analyzed. All patients received uninterrupted oral anticoagulation for at least 4 weeks prior to ablation and 3 months post-ablation. Both bleeding and thromboembolic events were assessed at 24 hours comparing patients on warfarin, rivaroxaban and edoxaban.

Results: Mean age of patients were 68.5 +/- 8 years in the warfarin group ( N =86), 63.4 +/- 10.6 years; in the edoxaban group ( N =63) and 62.3 +/- 11.6 years in the rivaroxaban group ( N =79). CHADSVASc scores were 2.43 +/- 1.34, 1.68 +/- 1.34 and 1.64 +/- 1.38 respectively. The mean left atrial sizes were 42.7 +/- 6.8 mm, 42.0 +/- 6 mm and 41.1 +/- 6.5 mm respectively. The study endpoint was death, acute thromboembolism or major bleeding. There was 1 pericardial effusion (1.2%) in the warfarin group, 1 pericardial effusion and 1 transient ischaemic attack (2.5%) in the rivaroxaban group and 1 pericardial effusion needing drainage (1.6%) in the edoxaban group. There were no significant differences in the study endpoints between groups.

Conclusion: This real-world study demonstrated no significant difference in safety and efficacy between uninterrupted edoxaban, warfarin and rivaroxaban in patients undergoing AF/flutter ablation.

Keywords: Anticoagulation; Atrial fibrillation; Catheter Ablation; Complications; Edoxaban.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study Method and Follow-up Flow Chart
Patients on uninterrupted anticoagulation 4 weeks prior to and 3 months post AF/flutter ablation with edoxaban were compared with those on rivaroxaban and warfarin. Records of assessment at 24 hours post-procedure were used to evaluate the occurrence of complications.
See this image and copyright information in PMC

References

    1. Viles-Gonzalez Juan F, Mehta Davendra. Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. Curr Cardiol Rep. 2011 Feb;13 (1):38–42. - PubMed
    1. Cardoso Rhanderson, Knijnik Leonardo, Bhonsale Aditya, Miller Jared, Nasi Guilherme, Rivera Manuel, Blumer Vanessa, Calkins Hugh. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018 Jan;15 (1):107–115. - PubMed
    1. Calkins Hugh, Willems Stephan, Gerstenfeld Edward P, Verma Atul, Schilling Richard, Hohnloser Stefan H, Okumura Ken, Serota Harvey, Nordaby Matias, Guiver Kelly, Biss Branislav, Brouwer Marc A, Grimaldi Massimo. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017 Apr 27;376 (17):1627–1636. - PubMed
    1. Cappato Riccardo, Marchlinski Francis E, Hohnloser Stefan H, Naccarelli Gerald V, Xiang Jim, Wilber David J, Ma Chang-Sheng, Hess Susanne, Wells Darryl S, Juang George, Vijgen Johan, Hügl Burkhard J, Balasubramaniam Richard, De Chillou Christian, Davies D Wyn, Fields L Eugene, Natale Andrea. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21;36 (28):1805–11. - PMC - PubMed
    1. Kirchhof Paulus, Haeusler Karl Georg, Blank Benjamin, De Bono Joseph, Callans David, Elvan Arif, Fetsch Thomas, Van Gelder Isabelle C, Gentlesk Philip, Grimaldi Massimo, Hansen Jim, Hindricks Gerhard, Al-Khalidi Hussein R, Massaro Tyler, Mont Lluis, Nielsen Jens Cosedis, Nölker Georg, Piccini Jonathan P, De Potter Tom, Scherr Daniel, Schotten Ulrich, Themistoclakis Sakis, Todd Derick, Vijgen Johan, Di Biase Luigi. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018 Aug 21;39 (32):2942–2955. - PMC - PubMed

LinkOut - more resources